Piper Sandler Initiates Coverage On NewAmsterdam Pharma with Overweight Rating, Announces Price Target of $37
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi has initiated coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with an Overweight rating and set a price target of $37. This suggests a positive outlook for the company's stock.

January 16, 2024 | 8:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NewAmsterdam Pharma receives an Overweight rating from Piper Sandler with a price target of $37, indicating a bullish stance from the analyst.
Analyst ratings, especially from reputable firms like Piper Sandler, can significantly influence investor sentiment and stock prices. An Overweight rating generally suggests that the analyst believes the stock will outperform the average return of the stocks in the analyst's coverage universe. The announcement of a price target of $37 also provides a specific expectation for the stock's potential upside, which can positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100